These results support the first clinical trial of ALRN-6924 in pediatric patients (ClinicalTrials.gov Identifier: NCT03654716), which specifically includes enrollment of patients with histological diagnosis of HB and wild-type TP53. The gene discussed is TP53; the disease is hemoglobin measurement.